Article Details
Retrieved on: 2021-05-14 11:15:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
ROCKVILLE, Md., May 14, 2021 /PRNewswire/ --. RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related ...
Article found on: www.citizentribune.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here